Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, PR China.
Radiat Oncol. 2010 Jul 30;5:68. doi: 10.1186/1748-717X-5-68.
To investigate the feasibility, and safety of 125I seed permanent implantation for recurrent head and neck carcinoma under CT-guidance.
A retrospective study on 14 patients with recurrent head and neck cancers undergone 125I seed implantation with different seed activities. The post-plan showed that the actuarial D90 of 125I seeds ranged from 90 to 218 Gy (median, 157.5 Gy). The follow-up was 3 to 60 months (median, 13 months). The median local control was 18 months (95% CI, 6.1-29.9 months), and the 1-, 2-, 3-, and 5- year local controls were 52%, 39%, 39%, and 39%, respectively. The 1-, 2-, 3-, and 5- survival rates were 65%, 39%, 39% and 39%, respectively, with a median survival time of 20 months (95% CI, 8.7-31.3 months). Of all patients, 28.6% (4/14) died of local recurrence, 7.1% (1/14) died of metastases, one patient died of hepatocirrhosis, and 8 patients are still alive to the date of data analysis.
CT-guided 125I seed implantation is feasible and safe as a salvage or palliative treatment for patients with recurrent head and neck cancers.
探讨 CT 引导下 125I 放射性粒子植入治疗复发性头颈部肿瘤的可行性和安全性。
回顾性分析 14 例接受不同活度 125I 放射性粒子植入治疗的复发性头颈部肿瘤患者。术后计划显示，125I 种子的实际 D90 范围为 90 至 218Gy（中位数，157.5Gy）。随访时间为 3 至 60 个月（中位数，13 个月）。中位局部控制时间为 18 个月（95%CI：6.1-29.9 个月），1、2、3 和 5 年局部控制率分别为 52%、39%、39%和 39%。1、2、3 和 5 年生存率分别为 65%、39%、39%和 39%，中位生存时间为 20 个月（95%CI：8.7-31.3 个月）。所有患者中，28.6%（4/14）死于局部复发，7.1%（1/14）死于远处转移，1 例死于肝硬化，8 例患者截至数据分析时仍存活。
CT 引导下 125I 放射性粒子植入术作为复发性头颈部肿瘤的挽救性或姑息性治疗是可行和安全的。
